Ganirelix
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ganirelix: From Controlled Ovarian Stimulation to Hypertrichosis
One-Sentence Summary
Ganirelix (DrugBank DB06785) is a GnRH (gonadotropin-releasing hormone) receptor antagonist; this evidence pack does not include a sourced Australian original-indication text, but the drug’s established clinical role is in controlled ovarian stimulation protocols in assisted reproduction. The TxGNN model predicts a possible link to hypertrichosis (disease), but no clinical trials and no literature currently support this specific prediction, and the evidence pack’s own mechanistic review flags it as likely model noise rather than a genuine signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not sourced from this evidence pack (no ARTG listing); GnRH antagonist class, established use in controlled ovarian stimulation (IVF) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in this evidence pack (flagged as a High-severity data gap). Based on the drug class information present in the pack’s own analysis, ganirelix is a GnRH receptor antagonist — its established pharmacology suppresses the hypothalamic-pituitary-gonadal axis to prevent premature LH surges during ovarian stimulation.
However, for this specific candidate, the pack’s mechanistic review explicitly states that no known pathway connects GnRH receptor antagonism to hair growth regulation, and that neither clinical trial nor literature evidence supports the association. The reviewer’s own assessment characterises this prediction as likely model noise rather than a meaningful signal, rather than a biologically plausible repurposing hypothesis. This should be read as a low-confidence output requiring independent biological rationale before any further investment.
Nine other candidates were scored in the same batch (ranks 2–10, including familial precocious puberty and aromatase excess syndrome). All returned zero clinical trials and zero (or non-specific) literature, and all were scored L5/Hold — none currently rises above hypothesis-generation status.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Ganirelix currently has no ARTG entries and is not marketed in Australia. No product/dosage-form information is available from this evidence pack.
Safety Considerations
No key warnings, contraindications, or drug-drug interaction data were returned for ganirelix in this evidence pack (TFDA/PI-equivalent labelling data is flagged as a Blocking data gap, and the DDI query returned no results). As this product is not currently TGA-registered, safety information should be sourced from the overseas manufacturer’s Product Information or an equivalent regulatory monograph before any clinical consideration.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical or literature evidence supporting a ganirelix–hypertrichosis link, no plausible mechanistic pathway has been identified, and the evidence pack’s own review treats the prediction as likely model noise. The drug is also not currently marketed in Australia.
To proceed, the following is needed:
- A validated mechanism-of-action source (DrugBank API confirmation) to properly assess biological plausibility
- TGA/PI-equivalent safety and labelling data (currently a Blocking gap)
- Any emerging clinical trial or literature evidence specific to ganirelix and hair-growth-related conditions
- Re-scoring once independent biological rationale (not just TxGNN score) can be established
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.